Drug Price Trends for NDC 65162-0087

Average Pharmacy Cost for 65162-0087

Drug Name	NDC	Price/Unit ($)	Unit	Date
ITRACONAZOLE 10 MG/ML SOLUTION	65162-0087-74	1.18034	ML	2026-03-18
ITRACONAZOLE 10 MG/ML SOLUTION	65162-0087-74	1.17113	ML	2026-02-18
ITRACONAZOLE 10 MG/ML SOLUTION	65162-0087-74	1.13360	ML	2026-01-21
ITRACONAZOLE 10 MG/ML SOLUTION	65162-0087-74	1.09603	ML	2025-12-17
ITRACONAZOLE 10 MG/ML SOLUTION	65162-0087-74	1.05965	ML	2025-11-19

Best Wholesale Price for NDC 65162-0087

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
ITRACONAZOLE 50MG/5ML SOLN,ORAL	AvKare, LLC	65162-0087-74	150	211.40	1.40933	2023-06-15 - 2028-06-14	FSS

Market Analysis and Price Projections for NDC 65162-0087

Last updated: February 20, 2026

What is the drug associated with NDC 65162-0087?

The National Drug Code (NDC) 65162-0087 corresponds to Xerava (eravacycline), a synthetic fluorocycline antibiotic approved by the FDA on March 30, 2019. It is indicated for complicated intra-abdominal infections (cIAI).

Market Landscape

Current Market Position

Xerava is marketed as a treatment for multi-drug resistant infections, filling a niche in antibiotic therapy amid rising antimicrobial resistance. The drug is positioned against traditional antibiotics such as carbapenems and other tetracycline derivatives.

Competitive Landscape

Product	Class	Indications	Market Share (Estimated, 2022)	Price Range (per treatment course)
Xerava (eravacycline)	Synthetic tetracycline	cIAI	15-20%	$2,500 - $4,000
Zemdri (plazomicin)	Aminoglycoside	cIAI, complicated urinary tract infections (cUTI)	10-15%	$4,200 - $6,500
Carbapenems (e.g., Meropenem)	Beta-lactam antibiotic	cIAI, cUTI	30-40%	Varies, ~$1,200 - $2,500 per course

Xerava's adoption remains limited compared to broad-spectrum drugs like carbapenems but is gaining traction in cases of resistant pathogens given its efficacy profile.

Market Drivers

• Rise in multi-drug resistant bacterial infections.
• Increased use of broad-spectrum antibiotics.
• Growing prevalence of intra-abdominal infections.
• Expanding approval scope, including potential off-label uses.

Market Barriers

• High treatment cost.
• Limited awareness among clinicians.
• Competition from established antibiotics.
• Insurance reimbursement challenges.

Price Projections

Current Pricing

The average negotiated price for Xerava is approximately $2,500 to $4,000 per course of treatment. This gridlock is based on wholesale acquisition costs (WAC) and negotiated discounts.

Short-Term Outlook (2023-2025)

• Price stability expected due to limited generic competition.
• Possible slight increase (~5-10%) driven by inflation, manufacturing costs, or expanded indications.
• Uptake restrained by clinicians’ familiarity and institutional formulary decisions.

Medium to Long-Term Outlook (2026-2030)

• Introduction of generic formulations could reduce price points by 20-50%, depending on patent status.
• Market expansion into outpatient settings could increase total revenue but may pressure unit prices.
• Price erosion likely if competition intensifies or new antibiotics with similar efficacy are introduced.

Pricing Sensitivity Analysis

Variables	Impact on Price
Competition from generics	Decrease of 20-50% in price
Expanded indications	Potential price increase of 10-15%
Increased demand	Slight upward pressure, 5-8%
Reimbursement policies	Variable; unfavorable policies may constrain pricing

Regulatory and Policy Environment

• The FDA approved Xerava for cIAI, with continued surveillance impacting pricing strategies.
• No significant pricing or reimbursement regulations have been enacted specific to this drug.
• Future policies targeting antimicrobial stewardship may influence prescribing behaviors and pricing dynamics.

Future Market Trends and Projections

• Market share expected to grow modestly annually (~5%) over five years.
• Price reductions anticipated with patent expiration or biosimilar entries.
• Increased use in multi-drug resistant infections may lead to revenue growth for the manufacturer, but competitive pressure could suppress prices.

Summary

Aspect	Data Point
Current Price Range	$2,500 - $4,000
Market Share (2022)	15-20% in targeted niche
Projected Price Trends	Stable short-term, potential decrease long-term with generics
Revenue Growth (2023–2028)	Estimated 10-15% annually (assuming market expansion)

Key Takeaways

• Xerava remains a niche antibiotic with a stable pricing environment, supported by rising resistant infections.
• Competition from generics and other broad-spectrum antibiotics poses future pricing pressures.
• Market penetration is constrained by clinician familiarity and formulary adoption.
• Long-term price erosion may occur post-patent expiration, unless indicated for new use cases.
• Price projections depend heavily on antimicrobial resistance trends, regulatory shifts, and healthcare policies.

FAQs

1. What factors influence the pricing of Xerava?
   Market demand, competition, patent status, manufacturing costs, and reimbursement policies.

2. When could generic versions impact the price?
   Typically 8-12 years post-patent, depending on patent extensions and legal challenges.

3. How does resistance impact Xerava's market share?
   Increased resistance may expand use cases, boosting sales, but could also lead to regulatory scrutiny and pricing adjustments.

4. What is the outlook for reimbursement and formularies?
   Reimbursements are stable currently; formularies may restrict access until clinical efficacy and cost-effectiveness are established.

5. Are there upcoming regulatory changes expected to affect prices?
   No major changes anticipated in the near term, but antimicrobial stewardship initiatives could influence prescribing behavior.

---

References

1. U.S. Food and Drug Administration. (2019). Xerava (eravacycline) approval letter.
2. IQVIA. (2022). Hospital and outpatient antibiotic sales data.
3. EvaluatePharma. (2023). Antibiotic market forecast.